Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Barron Von Hymen who wrote (195)	3/10/1998 6:17:00 PM
From: targetedmoab	Respond to of 656

My understanding is they are finsihed most of the phase III trials and will be presenting the data to the FDA by the end of the 2nd quarter......hopefully there will be an expidited NDA with approval by the end of the year. Looks like this stock is going to be a winner.

To: Barron Von Hymen who wrote (195)	3/11/1998 10:02:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 656

CEO Edward Fritzky was just on CNBC. CNBC noted that IMNX had just moved up about 5 points based on Phase II and Phase III data on Embrel treatment of RA. CEO gave some history. Initial trials were in advanced patients who had failed MTX. Now were moving to earlier patients who were still responding to MTX. Expects to file next quarter with approval at end of this year, beginning of next. Market includes 1/2 million end stage patients and 350,000 on MTX and 1 million earlier. This is an important week for IMNX because of yesterday's data, an allergy meeting on Saturday (results from asthma drug to be presented) and a meeting on Sunday (result for treating juvenile RA which has 70,000 patients and disease is fatal). Feed then cut out. CNBC then mentioned pipeline (RA and asthma). IMNX price quickly rose to 69 7/8.